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Abstract
The HPTN 067/Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking (ADAPT) study evaluated daily and 
non-daily dosing schedules for oral pre-exposure prophylaxis (PrEP) to prevent HIV. A qualitative sub-study including focus 
groups and in-depth interviews was conducted among men who have sex with men participating in New York City to under-
stand their experience with PrEP and study dosing schedules. The 37 sub-study participants were 68% black, 11% white, 
and 8% Asian; 27% were of Hispanic/Latino ethnicity. Mean age was 34 years. Themes resulting from qualitative analysis 
include: PrEP is a significant advance for HIV prevention; non-daily dosing of PrEP is congruent with HIV risk; and per-
vasive stigma connected to HIV and risk behavior is a barrier to PrEP adherence, especially for non-daily dosing schedules. 
The findings underscore how PrEP intersects with other HIV prevention practices and highlight the need to understand and 
address multidimensional stigma related to PrEP use.
Resumen El estudio HPTN 067/Dosificación Alternativa para Aumentar la Toma de Pastillas de la Profilaxis Pre-
Exposición (conocido por su sigla en inglés, ADAPT) evaluó tres estrategias, una diaria y dos no diarias, para la dosificación 
de la profilaxis pre-exposición oral (PrEP) para prevenir el VIH. Se realizó un sub-estudio cualitativo que incluyó grupos 
focales y entrevistas en profundidad con hombres que tienen sexo con otros hombres participando en el estudio en la Ciudad 
de Nueva York. El motivo del sub-estudio fue entender como los participantes experimentaron la PrEP y las estrategias de 
dosificación del estudio. Los 37 participantes del sub-estudio fueron 68% negro, 11% blanco y 8% asiático; 27% fueron de 
etnia hispana/latina. La edad media fue de 34 años. Los temas que resultaron del análisis cualitativo incluyen: La PrEP es un 
avance significativo para la prevención del VIH; hay una congruencia entre la dosificación no diaria de PrEP y los patrones 
del riesgo de VIH; y el penetrante estigma relacionado con el VIH es una barrera a la adherencia a la PrEP, especialmente 
para las estrategias de dosificación no diarias. Los hallazgos subrayan cómo la PrEP se intersecta con otras prácticas de pre-
vención del VIH y resaltan la necesidad de entender y abordar el estigma multidimensional relacionado con el uso de PrEP.
Keywords Pre-exposure prophylaxis · MSM · Stigma · Adherence · Sexual behavior
Introduction
Oral emtricitabine/tenofovir disoproxil fumarate (FTC/
TDF) as pre-exposure prophylaxis (PrEP) to prevent HIV 
acquisition was approved by the FDA in 2012 [1] and has 
the potential to alter the trajectory of the US epidemic if 
used by those at substantial risk for HIV, including men 
who have sex with men (MSM) [2, 3]. However, only about 
4% of MSM surveyed in the 2014 National HIV Behavioral 
Surveillance had taken PrEP in the last 12 months, a much 
lower proportion than the 25% estimated to meet behav-
ioral indications for PrEP [4]. Some potential barriers to 
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use of the currently approved daily PrEP regimen, such as 
the need for long-term adherence to a daily medication [5, 
6], users’ concerns about medication toxicity [7–10], and 
cost [9–11], may be mitigated by nondaily PrEP regimens 
[12–16]. Contextual factors, notably users’ perceptions and 
experiences of social attitudes about PrEP [17–20], can also 
influence its use. While perceived social norms concerning 
PrEP use and how PrEP fits into sexual practices have been 
explored hypothetically in qualitative research among people 
who would be potentially eligible to take PrEP [21–24], to 
date there is limited qualitative research exploring experi-
ences using open-label PrEP [18, 25–27], particularly for 
non-daily dosing [19].
The current analysis presents findings from a qualitative 
sub-study conducted among New York City participants in 
HPTN 067/Alternative Dosing to Augment Pre-Exposure 
Prophylaxis Pill Taking (ADAPT), a Phase II, randomized, 
open-label clinical trial comparing the feasibility and accept-
ability of alternative PrEP dosing schedules of oral FTC/
TDF. The qualitative sub-study focused on understanding 
contextual factors influencing participants’ use of PrEP, how 
participants fit PrEP into their established HIV prevention 
practices, and their preferences for dosing schedules.
Methods
Main Study Overview
Study methods and main results of HPTN 067/ADAPT 
have been described elsewhere [28–30]. In brief, the study 
assessed coverage of sexual intercourse events (defined as 
taking a pre-sex dose within 4 days prior to sex and tak-
ing a post-sex dose within 24 h following sex); the num-
ber of PrEP tablets required for coverage; and side effects 
(ClinicalTrials.gov NCT01327651). The study enrolled 
HIV-uninfected women in Cape Town, South Africa and 
HIV-uninfected MSM and transgender women (TGW) at 
sites in Harlem, New York City and Bangkok, Thailand. 
Recruitment methods varied by site. Harlem participants 
were recruited through a mix of community recruitment 
strategies, referrals from providers, word of mouth, and 
on-line advertising. Participants were randomly allocated 
1:1:1 to one of three unblinded, open-label PrEP dosing 
schedules for 24 weeks of self-administered dosing: the 
current FDA-approved daily regimen (a single FTC/TDF 
tablet once a day); twice-weekly doses of a single FTC/TDF 
tablet with an additional tablet within 2 h after sexual inter-
course (time-driven); or a single FTC/TDF tablet taken up 
to 48 h before sex and an additional tablet taken within 2 h 
after intercourse (event-driven). All participants received 
counseling on adherence to their assigned dosing schedule 
[31] and behavioral risk reduction, condoms and lubricant. 
Separate qualitative sub-studies including focus groups (FG) 
and individual in-depth interviews (IDI) were conducted at 
each study site to explore the social and cultural dimensions 
that could affect PrEP use.
Sub‑study Methods
Recruitment
Sub-study participants were recruited from the Harlem 
study sample of 179 participants. Potential participants 
were invited to participate in either FG or IDI after they 
had completed the 24 weeks of self-administered PrEP use 
and within 3 months of study completion. Separate FG 
comprised of participants from each arm were scheduled 
to include participants who enrolled at early and late inter-
vals during the main study follow-up period. Similarly, IDI 
with participants from each arm were scheduled at early 
and late intervals during the main study follow-up period. 
Convenience sampling was used to recruit FG participants; 
purposeful sampling [32] was used for IDI to capture the 
range of experiences with self-administered PrEP, includ-
ing difficulties adhering to the assigned dosing schedule or 
discontinuation of PrEP.
Data Collection
Following written informed consent, FG and IDI were con-
ducted in English by an experienced qualitative researcher 
who was not involved in main study procedures, so as to 
limit social desirability and reporting biases. Semi-struc-
tured interview guides (Tables 1 and 2) developed by the 
main study investigators included open-ended, exploratory 
questions and optional follow-up probing questions  that 
allowed participants to introduce topics relevant to their 
experience. Domains of inquiry included usual HIV preven-
tion practices before study participation; changes in sexual 
practices while in the study; acceptability and perceived 
feasibility of assigned dosing schedule; hypothetical prefer-
ences among the three schedules; and facilitators and barri-
ers to adherence. Demographic information was collected at 
the main study enrollment visit via interviewer-administered 
questionnaire and sexual risk behavior via computer-assisted 
self-interview at the main study randomization visit; data 
were abstracted for sub-study participants. 
Qualitative Data Analysis
Recorded FG and IDI were professionally transcribed, 
de-identified and entered into Dedoose, a web application 
for qualitative data analysis [33]. Three co-authors (JF, 
YH-M, ASL) reviewed and coded a subset of transcripts 
using a preliminary set of deductive codes derived from the 
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Table 1  Focus group guide
Understanding of schedule
Let’s begin by talking about the schedule that you were asked to follow for taking pills in this study
 1. What is your understanding of how you were asked to take pills in this study?
Probe: What is your understanding of what you were being asked to do with the pills that you got in this study?
Schedule fit to daily life (facilitators/challenges)
Now I’d like to ask you about how difficult or easy it was for you to follow the recommended schedule for taking pills
 2. What would you say were the main things that made this recommended schedule work well for you or fit into your life?
 3. What would you say were the main things that made this recommended schedule not work so well, or really fit well into your life? Were there times it 
was particularly hard to try to take the pills as recommended (prescribed)?
Feasibility/acceptability of assigned schedule
 4. For your recommended schedule, [define this for the group] what would you say about how acceptable it would be to people in general?
Probe: Who would it be good for? Who would it not fit well with?
 5. How reasonable is it to ask people to follow a pill-taking schedule that tells people to [use schedule definition]?
Schedule alterations
 6. Many people find it difficult to take pills exactly as they are recommended, for lots of reasons. Sometimes people change how they take pills to better 
suit their lives. Are there any times you can think of when you changed the recommended schedule in this study to better fit your life? Would you 
share with the group how you did this?
Probe to explore intentional changes to the schedule and any indications that people started and stopped study drug in relation to sexual activity
Ideal schedule
 7. What would your ideal schedule for taking these pills be? What would work best for you?
Preferences for other schedules
 8. Other schedules being studied include [provide details on schedules not assigned to this group and write each potential schedule on the flip chart: 
Daily (one tablet each day); Twice Weekly‐Plus (take a tablet on two separate days of the week plus a tablet after each time you have sex); Before and 
After sex (take one tablet a day or so before sex and shortly after sex)]. If all these schedules worked equally well to prevent HIV infection, which of 
these would you choose?
Perceptions of adherence support offered/provided
 9. At each visit that you were given study drug, a counselor asked you about your experiences with the study pills. What were those discussions like?
 10. How did those discussions affect your pill-taking, if at all?
 11. What kind of changes would you recommend for those discussions?
 12. Based on your experience, what would you recommend to help people who are not in a study take PrEP as their doctor recommends?
PrEP as part of/or in conflict with other prevention strategies
 13. Let’s talk about what you normally do that may protect you from getting HIV. What kinds of things do you normally do?
 14. When you started taking these tablets, did you notice a change in any of the other things that you normally would do to help to protect you from 
HIV?
Probe for (1) strengthening of other prevention practices and/or (2) weakening of non‐PrEP prevention practices and what the group perceived the 
reasons for these changes were.
Risk compensation
 15. When you started taking these tablets, did you notice a change in your sexual behaviors?
Probe for potential changes in number or types of partners, frequency of sex or engaging in different kinds of sex.
 16. Did taking the pills ever affect the way you thought about your risk of getting HIV? In what way(s)?
Probe for preventive misconception‐ that use of the study medication provided greater benefits than reasonably expected.
Social motivation/study connections
[Just a couple of questions left.]
 17. Did anyone close to you know about your participation in this trial?
Probe for partial disclosure of study procedures, e.g., did participants say that they were in a prep study but not that they were taking medication, or that 
they were on a specific dosing schedule.
 18. What kinds of things influenced your decision to tell people or not to tell people that you were in this study and/or that you were taking the study 
medication?
 19. What would you say about any support you got from people important to you, the study team members you worked with during your clinic visits, 
or other participants you met during visits or as a part of your involvement in the study? Did you get any support from others? What would be an 
example of that?
Recommendations
 20. Last question‐ Are there any observations or recommendations for the research team that you would like to offer that have not been discussed?
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guides, with additional codes identified and applied through 
grounded theory techniques of open coding and compara-
tive analysis [34]. The results were scrutinized to eliminate 
redundant or imprecise codes, clarify code definitions, and 
construct a coding schema used to code the entire set of 
transcripts [35]. The complete set of coded excerpts was 
reviewed by the larger team for inconsistencies and discrep-
ancies, which were resolved through an iterative process of 
discussion and re-coding [36]. A chart generated by Dedoose 
showing the presence or absence of codes in each transcript 
Table 2  In-depth interview guide
Understanding of schedule
 1. What is your understanding of the schedule for pill taking that you were asked to follow?
Schedule fit to daily life (facilitators/challenges)
Now I’d like to ask you about how difficult or easy it was for you to follow the recommended schedule for taking pills.
 2. What would you say were the main things that made this recommended schedule work well for you or fit into your life?
 3. What would you say were the main things that made this recommended schedule not work so well, or really fit well into your life? Were 
there times it was particularly hard to take the pills as recommended (prescribed)?
Feasibility/acceptability of assigned schedule
 4. For your recommended pill-taking schedule, what would you say about how acceptable it would be to people in general? Who do you think 
it would be good for? Who do you think it would not work well for?
 5. How reasonable is it to ask people to follow a schedule that tells people to take pills on the schedule that you had [use schedule definition]?
Schedule alterations
 6. Many people find it difficult to take pills exactly as they are recommended for lots of reasons. Sometimes people change how they take pills 
to better suit their lives. Are there any times you can think of where you changed the schedule to better fit your life?
Probe for intentional changes to the schedule and any indications that people started and stopped study drug in relation to sexual activity.
Ideal schedule
 7. What would your ideal schedule for taking these pills be for you?
Preferences for other schedules
 8. Other schedules being studied include Daily (one tablet each day); Twice Weekly‐Plus (take a tablet on two separate days of the week plus a 
tablet after each time you have sex); Before and After sex (take one tablet a day or so before sex and shortly after sex). If all these schedules 
for pill-taking worked as well as the others to prevent HIV infection, which of these would you choose?
Perceptions of adherence support offered/provided
 9. Each visit that you were dispensed study drug, a counselor asked you about your experiences with the study tablets. What were those discus-
sions like for you?
 10. How did those discussions affect your pill-taking, if at all?
 11. Would you recommend changes to those discussions?
 12. Based on your experience, what would you recommend to help people who are not in a study take PrEP as it is recommended to them?
PrEP as part of/or in conflict with other prevention strategies
 13. Let’s talk about what you normally do that can protect you from getting HIV. What kinds of things do you normally do (like condom use, 
talking about HIV status, getting HIV testing, limiting number of partners, and so on)?
Probe for strengthening of other prevention practices and/or weakening of non‐PrEP prevention practices and what the respondent perceived 
the reasons for these changes were.
Risk compensation
 14. When you started taking these tablets, did you notice a change in your sexual behaviors?
Probe for potential changes in number or types of partners, frequency of sex or engaging in different kinds of sex.
 15. Did taking the pills ever affect the way you thought about your risk of getting HIV? In what way(s)?
Probe for preventive misconception‐ that use of the study medication provided greater benefits than reasonably expected.
Social motivation/study connections
[Just a couple of questions left.]
 16. Did anyone close to you know about your participation in this trial? What kinds of things influenced your decision to tell people or not to 
tell people that you were in this study and/or that you were taking the study medication?
 17. What would you say about the kind of support you got from people important to you, the study team members you worked with during 
your clinic visits, or other participants you met during visits or as a part of your involvement in the study?
 18. Did you get any support from others? Can you describe that support to me?
Recommendations
 19. Last question‐ Are there any observations or recommendations for the research team that you would like to offer that have not been dis-
cussed?
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was scrutinized for indications of systematic differences 
in coding of FG and IDI. No systematic differences were 
observed (data not shown). Thematic analysis was then con-
ducted on a data set of coded excerpts from both FG and 
IDI to identify themes [37] that characterized perceptions, 
motivations, and experiences related to PrEP use.
Ethical Review and Participant Compensation
The main HPTN 067/ADAPT study and the sub-study were 
reviewed and approved by the Columbia University Medical 
Center Institutional Review Board. All participants provided 
written informed consent to participate in the main and sub-
studies. FG and IDI participants were compensated 50 dol-
lars and roundtrip public transportation fare.
Findings
As shown in Table 3, 37 of the 179 Harlem HPTN 067 
study participants completed either a FG (N = 31) or an 
IDI (N = 6). Participants in the qualitative sub-study had 
a mean age of 34 years. One IDI participant identified as 
gender queer; the remaining 36 sub-study participants identi-
fied as MSM. Sub-study participants were 68% black, 11% 
white, and 8% Asian; 27% identified as ethnically Hispanic 
or Latino. Sixty-eight percent were unemployed. Sub-study 
participants reported a mean of 5.7 sexual partners (range 
1–25) and a mean of 9.1 instances of condomless intercourse 
(range 0–55) in the 3 months preceding study randomiza-
tion. Sub-study participants did not differ significantly from 
other main study participants in demographic characteristics 
and in reported sexual behavior (data not shown). Consistent 
with the approach of recruiting participants around the time 
of their final study follow-up visit, sub-study participants 
had higher retention in scheduled follow-up study visits as 
compared to other main study participants (mean retention 
96.5% vs 82.9%; p < 0.001).
Qualitative analysis yielded three broad, interrelated 
themes: (1) PrEP is a significant advance for HIV preven-
tion; (2) Non-daily dosing of PrEP is congruent with the 
episodic nature of HIV risk; and (3) Pervasive HIV-related 
stigma directed at PrEP use is a barrier to adherence.
PrEP is a Significant Advance for HIV Prevention
Reflecting on how they protected themselves from HIV 
before using PrEP, participants described a combination 
of tactics that for most included at least some condom use, 
but also relied on their own assessment of the potential 
for HIV exposure that a given sexual partner represented 
and their ability to modify their own behavior accordingly. 
Some described this assessment as knowing a partner’s 
status, others as a nuanced evaluation of the risk repre-
sented by a potential partner.
“I’m not a condom user so what I did was I just try to 
keep my same partners…. And I know my partners’ 
status. So that was my safe sex. I knew their status.” 
FG Time-Driven Arm
“For me, if I was entertaining the thought of hav-
ing sex with him, now comes the thing of getting to 
know your character and knowing your history to see 
if you’re promiscuous or you’re the cheating type, or 
the lying type.” FG Event-Driven Arm
Several participants reflected that their habitual approach 
to prevention before using PrEP was fallible, resting as 
it did on their ability to discern risk in their partners or 
resist the temptation to engage partners who might expose 
them to HIV.
“Everything that look good to you ain’t good for you. 
Everything that glitters ain’t gold.” IDI Daily Arm
“Sometimes I am not able to say no when I need to say 
no when I know it is the best thing for me to say no, 
sometimes.” IDI Time-Driven Arm
In comparison to  their prior strategies, participants 
viewed PrEP as a groundbreaking advancement in HIV pre-
vention and expressed deep appreciation for its potential to 
protect them from HIV. Words and phrases used to describe 
what PrEP meant to the participants ranged from scientific 
Table 3  Qualitative sub-study participant demographics
a Includes European (2), not defined (2), and Native American (1)
FG (n = 31) IDI (n = 6) Total (n = 37)
Mean age 34 36 34
Gender identity
 MSM 31 (100%) 5 (83%) 36 (97%)
 Gender queer 0 (0%) 1 (17%) 1 (3%)
Race
 Black 21 (68%) 4 (67%) 25 (68%)
 White 3 (10%) 1 (17%) 4 (11%)
 Asian 3 (10%) 0% 3 (8%)
 Othera 4 (13%) 1 (17%) 5 (14%)
Hispanic ethnicity 9 (29%) 1 (17%) 10 (27%)
Unemployed 20 (65%) 5 (83%) 25 (68%)
Educational level
 Less than high school 7 (23%) 1 (17%) 8 (22%)
 High school 9 (29%) 3 (50%) 12 (32%)
 Technical training 2 (6%) 2 (33%) 4 (11%)
 Some college 6 (19%) 0% 6 (16%)
 College 7 (23%) 0% 7 (19%)
1144 AIDS and Behavior (2018) 22:1139–1149
1 3
to popular culture references and even included a description 
of HIV as a childhood adversary. The descriptions served 
to emphasize that PrEP was a true departure from previous 
strategies for HIV prevention.
“The biggest discovery in the last century was antibiot-
ics; man it’s saved so many lives. This is just as big as 
that to me.” FG Daily Arm
“It’s like having the Terminator by your side.” FG 
Event-Driven Arm
“I felt like I was protected. I was protected. Like that 
was my older brother and I was getting beat up by the 
bully, you know, at school.” IDI Time-Driven Arm
For some participants the alleviation of anxiety about HIV 
that PrEP afforded led to enriched sexual experiences.
“Maybe you’re a little bit more sexually liberated… 
aside from the condom it had to do with extra protec-
tion, so I would like – I would go a little extra hard, 
and if the condom broke, I wouldn’t be so scared.” FG 
Event-Driven Arm
“My sex life was reborn. Before, I wouldn’t have - 
but this had aroused – created a – it aroused a sense 
of curiosity, and I really rediscovered myself. I said, 
“Holy shit! Amen.” FG Daily Arm
“I’m doing things – I’m learning things that I should 
have been doing in my 20 s and 30’s…. [When] I was 
growing up – AIDS; boom…. Sex meant death.” IDI 
Daily Arm.
When asked how taking PrEP influenced their HIV pre-
vention practices, participants frequently described becom-
ing more aware of the need for prevention and adopting other 
protective behaviors during their time in the study.
“I think it changed my thought process a little bit. Like 
I thought about it a little more than I normally would 
have, like, ‘Am I really going to trust this pill to do 
this? Or should I just put this condom on, as well?’… 
Actually, I put more thought into it.” FG Daily Arm
“It made me reduce my partners by a huge amount…. 
Just taking the pills continually reminded me to protect 
myself from HIV. And one of the risks of having HIV 
is just having an excessive amount of sexual partners, 
and then having risky encounters.” FG Event-Driven 
Arm
Many participants explicitly rejected the notion that PrEP 
justified abandoning other prevention methods, and several 
emphasized the need to protect themselves against infections 
other than HIV.
“People just came up and asked me, like, ‘Hey, are 
you on the pill? Oh, good, so we can just like…’ – No, 
that’s not how it works for me.” FG Daily Arm
“This pill can help you but in conjunction with safer 
practices…. Because if you just take this one thing 
and not everything else it’s going to fall apart.” FG 
Event-Driven Arm
“It’s like I was bulletproof against the big package but 
the little packages could still slide up in there.” FG 
Time-Driven Arm
In contrast, a minority of participants acknowledged engag-
ing in situations that they might have avoided without PrEP. 
Some explicitly connected their amplified risk behavior to 
the use of drugs or alcohol.
“I kind of turned it up a little bit, because I was on the 
medication, but again, I’d go back to the fact that I was 
actively using drugs, so I wasn’t in my right frame of 
mind, and of course, being on the medication made me 
think, “Hey, man, I’m protected.” FG Event-Driven 
Arm
One participant recalled reflecting on and correcting an ini-
tial willingness to forgo usual protective behaviors while 
taking PrEP.
“It made me practice safe sex less, a little bit less than 
I would normally…. I felt kind of impervious to it, to 
catching HIV, because of the pill. I really had to check 
myself about that, I really did.” FG Time-Driven Arm
Non‑daily Dosing of PrEP is Congruent 
with the Episodic Nature of HIV Risk
Participants across study arms generally expressed prefer-
ences for non-daily dosing schedules, both because non-
daily dosing corresponded to patterns of sexual activity and 
because they believed side effects of the PrEP medication 
would be less with less frequent dosing.
“I’d rather do it when I have sex…. Like when I put 
on a condom, or the person I’m having sex with is put-
ting on a condom, that’s something I have to do in that 
moment, and not every day.” FG Event-Driven Arm
“I know sometimes I’m just not going to have sex for 
a week or so, because I just really don’t feel like it. 
And taking the pill when you know you’re not going 
to have sex kind of sucks because you know that it can 
cause kidney damage and bone density troubles.” IDI 
Daily Arm
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One participant who based his preference for dosing sched-
ule on the demonstrated efficacy of daily PrEP acknowl-
edged that a proven non-daily schedule would be preferable.
“I think if it will be like hundred percent proven, then 
the less the better, but until then, I will take it as much 
as they say.” FG Time-Driven Arm
Several participants reasoned that dosing frequency should 
be calibrated to the individual’s level of sexual activity.
“If people are having unprotected sex, then I think that 
they should take it every day. People that are… not 
really sexually active, I really think that twice a week 
would be a better suggestion for people like that. But 
people that are in a relationship and constantly having 
sex and intercourse and stuff like that, I think that they 
should take it every day.” IDI Time-Driven Arm
Some participants described acting on this rationale and 
adjusting their dose according to what they perceived as 
their level of risk.
“I did change my regimen a little bit when I found 
myself just being with a single partner for a bit over a 
month, so I wasn’t taking it nearly as much, because 
I didn’t feel I needed the prevention at the time.” FG 
Daily Arm
Despite the expressed preference for non-daily dosing, par-
ticipants in non-daily dosing arms agreed that intermittent 
dosing presented adherence challenges. Remembering regu-
lar non-daily doses was difficult on the time-driven schedule; 
in both time-driven and event-driven arms forecasting sex in 
order to plan for dosing around sex was a challenge.
“I’m not going to lie, the whole remembering to take 
the pill thing, being as how I was set to take it twice a 
week, not like it was every day, it was a little hard to 
remember.” FG Time-Driven Arm
“You never really know, you might think that you’re 
not going to have sex and then you have sex. I actually 
didn’t have [any pills] on me because I wasn’t think-
ing about sex and then it happened, and I was like so 
far away from home that I wouldn’t have been able to 
achieve it right after sex, like I was supposed to.” FG 
Time-Driven Arm
Several participants observed that sex-dependent doses were 
challenging if sex was accompanied by drug or alcohol use.
“Only if I was like getting high I would probably forget 
to take my “before” pill. Then I would take my “after” 
pill, definitely.” IDI Event-Driven Arm
Pervasive HIV‑Related Stigma Directed at PrEP Use 
is a Barrier to Adherence
In contrast to the positive effects that PrEP had on sexual 
experiences and the generally heightened awareness of pre-
vention that participants gained while in the study, expe-
riencing or anticipating stigmatizing attitudes surrounding 
PrEP use was reported across study arms.
“Some people saw the pills I was taking and they 
thought I was sick. Oh he got HIV, because he taking 
Truvada.” IDI Daily Arm.
A few participants described contesting stigmatizing atti-
tudes about PrEP in conversations with family and friends.
“[My mom] was like, “What does this mean? Are you 
trying to tell me that you have HIV?” And I said, “No, 
I’ll send an article – a news article – about what this is 
all about.” FG Daily Arm
However, the association with HIV infection was generally 
difficult to counter with facts about PrEP, as the following 
exchange among FG participants suggests.
“You say, ‘Yo, I’m on a PrEP regimen, dah–dah-dah.’ 
You can explain it. You can give them documents in 
front of them like this –”
“It’s not going to work.”
“- It’s not going to work. You know why? Because the 
only thing in their mind is AIDS.”
“Stigma.” FG Event-Driven Arm
Another type of stigma attached to PrEP related to the 
presumed promiscuity of PrEP users.
“One of my partners was like, ‘Whoa, whoa. What 
does this mean? What are you doing?’ In other words, 
indicating that just by taking the pill this means that 
I’m willy-nilly having unprotected sex.” FG Daily Arm
“When I was talking to guys online, there were a few 
of them that were just like – doesn’t matter if you’re on 
PrEP, I’d rather not have sex with you because I don’t 
know if PrEP works or you’re probably just like a big 
whore.” FG Time-Driven Arm
Some participants themselves acknowledged holding stig-
matizing attitudes about PrEP use.
“For me, if someone just said so-and-so’s using PrEP 
and I knew what PrEP was at that time, I would ques-
tion what is their HIV status…. [Or] they could just 
be very – really promiscuous.” FG Time-Driven Arm
One participant vividly imagined gossip spreading through 
his social circle and extending to the workplace, ultimately 
impacting his job.
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“You could tell somebody [that you are taking PrEP] 
and no more than 10  minutes later… the whole 
neighborhood is saying, ‘Bob said he is taking them 
sex pills!’ His friend then told Tom and Tom done 
told Mary. Now look, when you get to work Monday 
they are telling you need a physical… and you say-
ing, ‘What, boss? I just had a physical.’ The rumors 
started in Manhattan and you work in the Bronx. 
How do they get there?” FG Event-Driven Arm
To avoid negative reactions, participants were wary of 
disclosing their PrEP use to others.
“I confided in myself. I didn’t tell nobody, because I 
know people judge you; taking pills they think you’re 
sick, something wrong with you, so I just kept it to 
myself” FG Event-Driven Arm
In addition to stigmatizing reactions from family and 
friends about PrEP use, participants also described antici-
pating or experiencing stigma when taking PrEP tablets 
after a sexual encounter. Some participants assigned to 
non-daily dosing arms developed strategies to hide post-
sex doses from their partner. One participant described 
hiding PrEP tablets in a mint box that he kept nearby dur-
ing sexual encounters.
“You can have it [and tell your partner] - ‘One min-
ute, hold on, let me go to the bathroom.’ Pop [the 
tablet in the bathroom], because… some people are 
not ready to just accept things. They live in - in a 
fantasy world where you don’t think it can happen to 
you.” FG Event-Driven Arm
Others described difficult interactions with partners who 
saw the tablets.
“I didn’t want to have them with me where the other 
person would find it because it was uncomfort-
able. Somebody did find them and I had to do some 
explaining, or it would have gotten into a big ugly 
fiasco.” FG Event-Driven Arm
“When I was having sex, I would take the pills and 
my partners would be like, ‘Why are you taking 
those pills?’… Sometimes it would never get to the 
intercourse part. It would just stop the night. They 
would be mad and leave.” IDI Time-Driven Arm
Similarly, some participants who were assigned to the 
daily dosing schedule saw the appeal of taking PrEP in 
conjunction with sex but anticipated that it would be dif-
ficult to disclose pill-taking to sexual partners.
“I really like the before sex [schedule]. I mean, but 
then again, it would have been awkward if the guy 
sees me taking my pill and he’s like – oh, what are you 
taking? And then I have to go and explain the pill and 
I don’t want to do that.” FG Daily Arm
Discussion
The mainly black MSM participants in the Harlem 
HPTN067/ADAPT qualitative sub-study saw PrEP as a 
valuable addition to their existing HIV prevention strate-
gies, which were based in part on their ability to discern 
risk in their partners and adjust their behavior accordingly. 
Participants commonly described a heightened awareness of 
prevention while taking PrEP and adopting additional pro-
tective behaviors, perhaps in part due to the regular coun-
seling and HIV testing they received as part of study partici-
pation. At the same time, a minority of participants reported 
increased willingness to engage in sexual encounters that 
might put them at risk for HIV, similar to the reductions 
in condom use among some PrEP patients that has been 
noted in clinical practice settings [38]. The experience of 
recognizing and correcting increased risk behavior while on 
PrEP has been identified in other qualitative studies of PrEP 
use [39], highlighting that individual prevention practices 
are responsive to both perceptions of situation-specific risk 
and the internalization of support for practicing prevention 
behaviors [40, 41].
In keeping with a situation-specific perspective on risk for 
HIV, Harlem sub-study participants frequently conceptual-
ized adherence to PrEP as situational. They related the need 
to take PrEP to periods of condomless sex, number of cur-
rent sexual partners, and other factors contributing to HIV 
risk such as substance use during sexual encounters. This 
perspective on taking PrEP is consistent with the emergent 
paradigm of ‘prevention-effective’ adherence to PrEP, in 
which the success of PrEP rests on accurately recognizing 
the potential for exposure to HIV and utilizing other preven-
tion tools appropriately, in addition to achieving adequate 
adherence to PrEP medication [42]. The findings presented 
here suggest that dynamic approaches to PrEP aligned 
with levels of exposure to HIV, including non-daily dosing 
schedules, would be acceptable to potential users. However, 
Harlem participants noted challenges to such approaches, 
including establishing routines for intermittent pill taking, 
forecasting sexual encounters, having medication available 
proximate to sex, and managing sexual partners’ attitudes 
about PrEP. Strategies for helping PrEP users recognize 
patterns of situational risk and adopt appropriate preven-
tion practices such as limiting the number of sexual partners 
and ensuring that condoms are available may be a valuable 
addition to counseling on adherence to PrEP [42]; further 
implementation research on the optimal components of sup-
port for PrEP is needed.
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The most vividly-described challenges that participants 
reported experiencing with sex-dependent dosing involved 
hiding PrEP use from sexual partners and dealing with part-
ners’ negative response if participants disclosed PrEP use. 
Paradoxically, even as participants became more aware of 
their need for prevention and strengthened their prevention-
related practices, they reported experiencing or anticipat-
ing stigmatizing attitudes from family, friends and sexual 
partners who interpreted the use of a recognized anti-HIV 
medication as an indication of being HIV-infected or associ-
ated PrEP use with promiscuity and exceptionally high risk 
for HIV.
Stigma related to both HIV and sexual promiscuity is 
a recognized barrier to PrEP uptake and use [17, 23, 43, 
44]. Research into attitudes on PrEP use among the gen-
eral population in the US documents that stigma regard-
ing PrEP is influenced by existing frameworks of stigma, 
so that PrEP use among stigmatized groups, notably black 
MSM, is viewed more negatively than PrEP use among the 
general population [45]. Our study adds a layer of complex-
ity to our understanding of how stigma impacts on PrEP 
use, highlighting the challenge stigma may present for sex-
dependent PrEP dosing. This finding is relevant to efforts to 
extend the findings of the ANRS IPERGAY study, in which 
a dosing strategy of two tablets of FTC/TDF two to 24 h 
before sexual intercourse and a third and fourth tablet at 
24- and 48-h intervals after the first dose demonstrated 86% 
relative reduction in risk of HIV infection among MSM and 
TGW in a placebo controlled trial [16] and 97% relative risk 
reduction in the follow-on open-label. Further exploration 
of how stigma related to promiscuity and HIV treatment 
intersects with HIV prevention strategies and how it can be 
mitigated at the social and interpersonal level is critical [43, 
44, 46, 47].
Limitations
These findings are subject to several limitations. The sub-
study enrolled a convenience and purposive sample of 
mostly black MSM in New York City that is not general-
izable to other populations in other areas. Although staff 
endeavored to reach study participants who had missed study 
visits to invite them to participate in the qualitative study, 
sub-study participants were significantly more likely to be 
retained in study follow-up visits than were other main study 
participants. Participants who were able to be reached and 
willing to participate in qualitative FG and IDI may be dif-
ferent than those who could not be reached or were unwill-
ing to participate in the qualitative research. The group set-
ting may have inhibited FG participants from voicing some 
opinions or sharing some experiences. Finally, the sub-study 
recruitment procedures were not designed to ensure par-
ticipation by TGW participants in the main study and the 
sub-study sample included no TGW. TGW are dispropor-
tionately impacted by HIV and evidence suggests that they 
may experience elevated challenges adhering to PrEP [48]; 
more research into the experience of this highly vulnerable 
group is crucial.
Strengths
Our sub-study engaged mostly black MSM, a group highly 
impacted by HIV in the US [49]. They lived in an area with 
high HIV prevalence and were largely unemployed, a factor 
associated with likelihood of HIV infection among black 
MSM [50]. Thus, they represent a group likely to benefit 
from the successful implementation of PrEP in the US [51]. 
Unlike most qualitative studies conducted outside of PrEP 
efficacy trials, participants had completed several months of 
open label PrEP and the data reflect that experience rather 
than anticipated or hypothetical perceptions, preferences, 
barriers and facilitators.
Conclusions
As PrEP uptake in the US grows, the need for interventions 
to support its effective use becomes ever more urgent. The 
qualitative data presented here highlight critical areas of 
needed support, including integrating PrEP into other pre-
vention strategies, adherence interventions for dosing sched-
ules that are congruent with patterns of sexual activity and 
intensifying efforts to counter PrEP-related stigma. The find-
ings are particularly relevant in characterizing PrEP-using 
experiences of Black MSM—a crucial population for HIV 
prevention efforts in the US.
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